Journal of Clinical Oncology · 1990 · 68 citations · 2 references
MedicineOncologyPharmacologyChemotherapyPediatric Clinical PharmacologyPediatric OncologyAdverse Effects Of ChemotherapyDrug-induced NeurotoxicityHigh-dose ChemotherapyPediatric ChemotherapyPharmacokinetics In Children With CancerToxicity Risk AssessmentChemotherapy-related ToxicityIfosfamide-based TherapyNeurotoxicityPharmacokinetics Of Cytotoxic ChemotherapyRelative Risk EstimationTreatment-related Neurotoxicity
Neurotoxicity developed in 22 of 97 children and adolescents with malignant solid tumors treated within a phase II ifosfamide protocol. The occurrence of neurotoxicity was related to previous cumulative dosages of cisplatin. One third of the patients who had received more than 600 mg/m2 of cisplatin developed this complication. The relative risk increased 3.2-fold with previous cisplatin dosages above 301 to 600 mg/m2, and 4.1-fold with dosages of 601 to 1,340 mg/m2. The increased risk of neurotoxicity in patients who had received more than 600 mg/m2 of cisplatin may be related to either a decreased clearance of ifosfamide itself or of the drug's active metabolites.
2
Phase II trial of ifosfamide in children with malignant solid tumors.
C B Pratt, Marc E. Horowitz, William H. Meyer et al. · PubMed · 1987 · 78 citations
Medicine, Oncology, Pharmacology +13